Presentation is loading. Please wait.

Presentation is loading. Please wait.

Measuring Angiogenesis in Hematologic Diseases

Similar presentations

Presentation on theme: "Measuring Angiogenesis in Hematologic Diseases"— Presentation transcript:

1 Measuring Angiogenesis in Hematologic Diseases
Maher Albitar, MD Quest Diagnostics, Nichols Institute San Juan Capistrano, CA 92690 (949) Steve Potts, Ph.D. Ravi Dayana Allen Olson, Ph.D. Aprio

2 Angiogenesis in Bone marrow

3 Variation in Angiogenesis Between Patients with Leukemias

4 Expression of Vascular Endothelial Growth Factor (VEGF) in Leukemic Cells
CML-Plasma CML-Plasma CML-Cells CML-Cells CLL AML N N 1 2 3 4 5 6 7 8 kD 57 45 VEGF 43 38 ACTIN

5 Angiogenesis Vs. Hematpoiesis in Hematologic Diseases:
Antiangiogenic Agents: Antibodies: Anti-VEGF, CDP860, Cotara, Erbitux.. Small Molecule Tyrosine Kinase inhibitor: AZD2171, BAy , PTK787/ZK, SU Other: Thalidomide,… Proangiogenic/Anti-angiogenic Factors: VEGF (multiple forms), bFGF, tal-1, Cox2, tie1, PIGF, PD-ECGF, HGF, MMP, PDGF, TNF-a, Angiogenin, TGF-a/b, G-CSF, VEGFR1/VEGFR2, NP1/NP2, ..... Autocrine Paracrine Endothelial Cells Paracrine Leukemia/Lymphoma Cells Stromal Cells

6 Increased Angiogenesis in Bone Marrow in Patients with Hematologic Diseases (Manual Measurement)
-IHC: FVIII antigen-positive endothelial cells -Digitized images are analyzed for: 1. Number of blood vessels/10 fields (200X) 2. Lumen area/10 fields (200X) using NIH Image software

7 High Levels of Plasma Angiogenic Factors in Leukemias and MDS

8 Intracellular VEGF is an Independent Prognostic Factor in AML and MDS

9 Measuring Angiogenesis (Microvessel Density)
Poor Reproducibility Time consuming and laborious Requires pathology background Not cost-effective Of marginal clinical Value No standardization How about Automation? Accuracy? Reproducibility? Clinically useful? Standardization between laboratories

10 Automation in Measuring Angiogenesis
Define sampling area: 5-10 rectangles representative of the sample (Automation in progress) Calculate the space in these rectangles

11 Measuring Vascular Areas by Measuring Factor VIII+ Area
Highlight brown (DAB)-stained Potentially: Define micro vessel boundary Find lumen regions (Holes) within micro vessels

12 Subtracting Megakaryocytes from Measured Vascular Area
Hematoxyline stain with heavy Anti-Factor VIII are filtered out with colocalization algorithm

13 Measuring Partial Vascular Areas
Find Micro Vessels (watershed) Find & Fill Lumen Holes Double Threshold Find Micro Vessel Boundary Find Lumen regions Watershed segmentation

14 Measuring Vascular Area relative to Hematopoietic Area/Cells (Vasc/Hem)
Hematoxyline-stained area or individual cells can be counted in the same rectangles tested for angiogenesis.

15 High Concordance Between Hmatopoietic Cell Number and Hematopoietic Area

16 Significant Correlation Between Manual and Automated Vascular Area Measurements

17 Correlations of Automated Angiogenesis Measurements

18 Clinical Correlations in Patients with Acute Myeloid Leukemia and Myelodysplastic syndrome (MDS)
AML MDS Valid R-value p-level Vasc/Hem & Days to respond 25 0.24 0.26 17 0.50 0.04 Vasc/Hem & Cytogenetic groups 0.35 0.08 -0.22 0.40 Vasc/Hem & PLT 0.38 0.06 0.05 0.84 & % Lymph in BM 0.17 0.43 Vasc/Hem & TDT in Blasts 21 -0.35 0.12 13 0.14 & CD64 -0.50 0.02 12 -0.11 0.74 Vascular area (%) & TPO 10 -0.58 11 0.13 0.71 & AGE Grouping at 70 -0.24 0.25 -0.40 0.11 & Perform status 0.42 0.41 0.10 & PS grouping -0.25 0.22 0.44 0.39 0.00 1.00 & HGB 0.21 -0.38 0.85

19 Distribution of Vascularity and Vasc/Hem in Patients with AML

20 Distribution of % Vascularity and Vasc/Hem in Patients with MDS

21 Higher Vasularity (% Vascular Area) is Associated with Longer Survival in MDS

22 Higher Vasular/Hematopoietic Area is Associated with Longer Survival in MDS

23 No correlation between Angiogenesis and Survival in AML

24 Higher Vasular/Hematopoietic Area is Associated with Shorter Remission Duration in AML

25 Summary Measuring Vascularity may Provide a surrogate marker for clinical behavior Automation in measuring angiogenesis is a reliable means for standardizing measurement of angiogenesis Automation allows the measurement of: Vascular Area (%) Hematopoietic cellularity Vascular Area relative to cellularity (Vasc/Hem) Larger studies are needed for clinical and biological correlations Further studies are needed to correlate with response the anti-angiogenic therapy

Download ppt "Measuring Angiogenesis in Hematologic Diseases"

Similar presentations

Ads by Google